{"id":21942,"date":"2025-04-28T22:26:16","date_gmt":"2025-04-28T15:26:16","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=21942"},"modified":"2025-04-28T22:26:16","modified_gmt":"2025-04-28T15:26:16","slug":"small-lab-co-ltd-obtains-fda-otc-approval-leading-the-k-beauty-wave","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=21942","title":{"rendered":"Small Lab Co., Ltd., obtains FDA OTC approval. Leading the K-Beauty wave"},"content":{"rendered":"

SEOUL, South Korea<\/span><\/span>, April 28, 2025<\/span><\/span> \/PRNewswire\/ — SmallLab Inc<\/a>, a<\/span>\u00a0microneedle platform company, has received final approval from the U.S. Food and Drug Administration (FDA) for its over-the-counter (OTC) drug manufacturing facility.<\/p>\n

\n

\"Image <\/a>
Image povided by Smalllab Inc.<\/span><\/p>\n<\/div>\n

The approval follows a Good Manufacturing Practice (GMP) inspection conducted in October.<\/span><\/p>\n

SmallLab received a VAI rating, indicating that only one minor observation was noted, which was fully resolved by December. This rating also reflects the FDA’s<\/span> recognition and trust in the company’s<\/span> quality management practices.<\/p>\n

Since 2022, SmallLab has operated a smart factory for OTC-grade pharmaceutical production, exporting its products to the U.S., Europe<\/span>, and beyond. With this FDA approval, the facility is now officially recognized as GMP-compliant for OTC drug manufacturing.<\/p>\n

Leveraging its proprietary large-area (LSCR) microneedle technology, SmallLab is developing microneedle patch pharmaceuticals formulated with a variety of active ingredients. The company aims to become a global leader in OTC contract manufacturing.<\/p>\n

CEO James Lee<\/span> stated, “We put human health and beauty first. With our microneedle technology, we aim to lead the global market and maximize customer satisfaction.”<\/p>\n

Previously selected as a Daejeon Star Company and a Promising SME, SmallLab has been recognized for its technological excellence. As an ODM company, it supplies OTC acne patches, serums, and sunscreens. <\/span>This FDA approval further\u00a0solidifies<\/span> its position as a small but\u00a0powerful<\/span> player on the global stage.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

SEOUL, South Korea<\/span><\/span>, April 28, 2025<\/span><\/span> \/PRNewswire\/ — SmallLab Inc<\/a>, a<\/span>\u00a0microneedle platform company, has received final approval from the U.S. Food and Drug Administration (FDA) for its over-the-counter (OTC) drug manufacturing facility.<\/p>\n

\n

\"Image <\/a>
Image povided by Smalllab Inc.<\/span><\/p>\n<\/div>\n

The approval follows a Good Manufacturing Practice (GMP) inspection conducted in October.<\/span><\/p>\n

SmallLab received a VAI rating, indicating that only one minor observation was noted, which was fully resolved by December. This rating also reflects the FDA’s<\/span> recognition and trust in the company’s<\/span> quality management practices.<\/p>\n

Since 2022, SmallLab has operated a smart factory for OTC-grade pharmaceutical production, exporting its products to the U.S., Europe<\/span>, and beyond. With this FDA approval, the facility is now officially recognized as GMP-compliant for OTC drug manufacturing.<\/p>\n

Leveraging its proprietary large-area (LSCR) microneedle technology, SmallLab is developing microneedle patch pharmaceuticals formulated with a variety of active ingredients. The company aims to become a global leader in OTC contract manufacturing.<\/p>\n

CEO James Lee<\/span> stated, “We put human health and beauty first. With our microneedle technology, we aim to lead the global market and maximize customer satisfaction.”<\/p>\n

Previously selected as a Daejeon Star Company and a Promising SME, SmallLab has been recognized for its technological excellence. As an ODM company, it supplies OTC acne patches, serums, and sunscreens. <\/span>This FDA approval further\u00a0solidifies<\/span> its position as a small but\u00a0powerful<\/span> player on the global stage.<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-21942","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/21942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21942"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/21942\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}